ADURO BIOTECH, INC. (NASDAQ:ADRO) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Set forth below are the proposals voted upon at the Annual Meeting (the “Annual Meeting”) of Stockholders of Aduro Biotech, Inc. (the “Company”) held on June6, 2018 at the Company’s offices at 740 Heinz Avenue, Berkeley, California 94710, along with the final voting results thereon:
Proposal 1—To elect the two ClassIII directors named below to serve until the 2021 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified. Each of the two named nominees was so elected, with the votes thereon at the Annual Meeting as follows:
| Final Voting Results | |||
|
Nominees |
For | Withheld | Broker Non-Votes |
|
Gerald Chan, D.Sc. |
57,981,120 | 3,406,582 | 8,000,918 |
|
Stephanie Monaghan O’Brien |
57,986,053 | 3,401,649 | 8,000,918 |
Proposal 2— To ratify the selection by the Audit Committee of the Board of Directors of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:
|
Final Voting Results |
|||
|
For |
Against |
Abstain |
BrokerNon-Votes |
|
68,798,343 |
585,506 | 4,771 | — |
About ADURO BIOTECH, INC. (NASDAQ:ADRO)
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
